CTLA4 and melanoma: Immune checkpoint inhibitors (ICI), e.g., monoclonal antibodies targeting cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4), programmed cell death protein-1 (PD-1) and PD-ligand 1 (PD-L1), have revolutionized the treatment of advanced melanoma.